Vaccine for preventing toxoplasma infection and application thereof

Abstract

The invention provides a vaccine for preventing toxoplasma infection. The vaccine contains nucleotide sequences selected from the followings: 1) 736-2385th nucleotide sequences as shown in SEQ ID No.1, and/or 759-2411th nucleotide sequences as shown in SEQ ID No.3; 2) nucleotide sequences complementary with the nucleotide sequences as shown in 1); and 3) nucleotide sequences which perform substituting, deletion and addition modification on one or a plurality of basic groups of the nucleotide sequences as shown in 1) or 2). The vaccine has the capability of effectively preventing and controlling the infection of a toxoplasma animal model (Kunming mice), and the combination of recombinant plasmids can effectively improve the immune effect of a single-gene vaccine, therefore, plasmids pVAX-ROP5 and pVAX-GRA15 can be used as DNA (Deoxyribose Nucleic Acid) vaccine candidate antigens for preventing the toxoplasma infection; and a combined immune vaccine of a recombinant plasmid based on such two genes can be used as a cocktail composite vaccine for preventing the toxoplasma infection.

Description

technical field [0001] The invention belongs to the fields of immunology and molecular biology, and in particular relates to a vaccine for preventing toxoplasma gondii infection. Background technique [0002] Toxoplasma gondii is a zoonotic pathogenic protozoan with worldwide distribution. Healthy adults generally have no clinical symptoms after infection, but Toxoplasma gondii is very harmful to people with immune system deficiency or immunosuppression, such as pregnant women, AIDS patients, and organ transplant patients, and even causes death. In addition, Toxoplasma gondii often causes abortion or congenital infection of domestic animals such as goats and sheep, causing serious economic losses to animal husbandry production. Moreover, domestic animals infected with Toxoplasma gondii are also the main route of transmission for human infection. In view of the limited ability of drugs to treat toxoplasmosis and the characteristics of high toxicity and side effects, immunop...

AI Technical Summary

Problems solved by technology

[0003] At present, DNA vaccines have been used against parasites such as: schistosomes, roundworms, especially in protozoa, including Plasmodium, Leishmania, Trypanosoma and other parasites It has been widely used in prevention and treatment, and the vaccine research against Toxoplasma infection has also entered a new stage. However, the research on nucleic acid vaccines against Toxoplasma gondii has not achieved satisfactory results.

The reason is that the life cycle of Toxoplasma gondii is complex, the morphology is diverse, the host range is wide, the immunogens of different antigens are also different, and the pathogenic mechanisms of its cysts and tachyzoites are also different. Vaccine candidate antigen based on a single antigenic component, but it is difficult to form effective resistance against Toxoplasma attacks and infects in different forms, so it is difficult to achieve the desired effect with only a few candidate antigen genes, and to find more and better DNA vaccine candidate antigens derived from different stages of Toxoplasma, especially with Toxoplasma Antigen gene related to virulence is an important way to study anti-toxoplasma gondii vaccine

Images